This study will assess the feasibility of utilizing a reduced intensity conditioning regimen,
in the setting of haploidentical transplantation, for patients with recurrent acute
lymphoblastic leukemia (ALL), AML and high risk or refractory solid tumors. In addition, the
feasibility and safety of administering post-transplant NK cell infusions will be evaluated.
Data obtained from this study will help determine the efficacy of allogeneic HSCT in the
treatment of pediatric sarcomas and add to the small body of literature utilizing
haploidentical HSCT to treat acute leukemia in pediatric patients. This study will also
further elucidate the role of NK cells in mediating a graft vs. tumor effect in allogeneic
HSCT. The main benefit to society is that this study will explore a novel therapy for
children with highly refractory cancer who are felt to be incurable with conventional
approaches. If feasibility is demonstrated, and there is evidence of anti-tumor activity,
then this will open up a new area of clinical research to better define the efficacy of this
approach for specific childhood malignancies.
- Solid tumors that have failed auto transplant or are ineligible to receive auto
- Relapsed AML in 1st relapse or 2nd or 3rd CR
- Relapsed ALL if they fail to attain an initial remission or if they relapse within 1
year following the discontinuation of chemotherapy.
- Greater than or equal to 6 months and <26 years old
- Suitable haploidentical donor available
- Leukemia with >25% blasts in bone marrow at the time of admission to the HSCT unit.
- Serum bilirubin >3 mg/dl
- GFR <40 ml/min/1.73 mw
- Cardiac left ventricular ejection fraction <40%